Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321257 | 0.92 | LRRK2 (0.45) | LRRK2ALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4326375 | 0.90 | MGLL (0.43) | LRRK2ALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4418577 | 0.86 | SLC6A7 (0.42) | LRRK2ALDH1A1HPGDSLC6A7 | |
| SCHEMBL4419775 | 0.82 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4315437 | 0.81 | MEN1 (0.53) | KDM4EALDH1A1HPGD | |
| SCHEMBL4324013 | 0.80 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4324183 | 0.80 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4418572 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4312356 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL4321312 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | KDM4E 1411/4885RECQL 3890/4885LRRK2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.